Sandra Peterson - Johnson Johnson Chairman

<div class='circular--portrait' style='background:#FF6600;color: white;font-size:3em;padding-top: 35px;;'>JNJ</div>
JNJ -- USA Stock  

Fiscal Quarter End: March 31, 2020  

Ms. Sandra E. Peterson is no longer Executive Vice President Group Worldwide Chairman of the Company effective October 1, 2018. Ms. Peterson joined the Company in 2012 as Group Worldwide Chairman and a member of the Executive Committee. Prior to joining the Company, Ms. Peterson was Chairman and Chief Executive Officer of Bayer CropScience AG in Germany, previously serving as President and Chief Executive Officer of Bayer Medical Care and President of Bayer HealthCare AG Diabetes Care Division. Before joining Bayer in 2005, Ms. Peterson held a number of leadership roles at Medco Health Solutions . In April 2016, Ms. Peterson was named Executive Vice President, Group Worldwide Chairman of Johnson Johnson. Ms. Peterson is responsible for the Companys consumerfacing businesses, including the consumer family of companies and the consumer medical device businesses the Companys medical device businesses and for supply chain, quality, information technology, and design across the enterprise.
Age: 58  Chairman Since 2017      
732 214-0332
Peterson was named Executive Vice President, Group Worldwide Chairman of Johnson & Johnson. Effective June 1, 2017, Ms. Peterson will assume leadership of the Hospital Medical Device business, in addition to her current responsibilities.

Sandra Peterson Latest Insider Activity

Management Efficiency

The company has 30.43 B in debt with debt to equity (D/E) ratio of 50.0 . This implies that the company may be unable to create cash to meet all of its financial commitments. Johnson Johnson has Current Ratio of 1.3 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Daniel VasellaNovartis AG
Moncef SlaouiGlaxoSmithKline PLC
Kenneth FrazierMerck Company
Brenton SaundersAllergan Plc
Paul BisaroAllergan Plc
Ian ReadPfizer
Lamberto AndreottiBristol Myers Squibb Company
Leif JohanssonAstrazeneca PLC
Daniel ODayGilead Sciences
Enrico VanniNovartis AG
Giovanni CaforioBristol Myers Squibb Company
Alex KrauerNovartis AG
John MartinGilead Sciences
John LechleiterEli Lilly And Company
Joerg ReinhardtNovartis AG
Ulrich LehnerNovartis AG

Entity Summary

Johnson Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. The company was incorporated in 1887 and is based in New Brunswick, New Jersey. Johnson Johnson operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 135100 people.Johnson Johnson (JNJ) is traded on BATS Exchange in USA. It is located in One Johnson and Johnson Plaza, New Brunswick, NJ 08933, United States and employs 135,100 people. Johnson Johnson is listed under Pharmaceutical Products category by Fama And French industry classification.

Johnson Johnson Leadership Team

A Washington, Independent Director
Jennifer Doudna, Independent Director
Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee
William Perez, Independent Director
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer
Marillyn Hewson, Independent Director
Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer
Mary Coleman, Independent Director
Michael Ullmann, VP, General Counsel and Member of Executive Committee
Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals
Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer
Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals
Mary Beckerle, Independent Director
Sandra Peterson, Group Worldwide Chairman and Member of Executive Committee
Scott Davis, Director
Louise Mehrotra, Vice President Investor Relations
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices
Ronald Williams, Independent Director
Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer
D Davis, Independent Director
Hubert Joly, Director
Anne Mulcahy, Lead Independent Director
Joseph Wolk, Chief Financial Officer, Executive Vice President
Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer
Ian Davis, Independent Director
Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive Committee
Mark McClellan, Independent Director
Charles Prince, Independent Director
Eugene Washington, Independent Director
Dominic Caruso, CFO, VP of Fin. and Member of Executive Committee
Peter Fasolo, Chief Human Resource Officer, Executive Vice President
Susan Lindquist, Independent Director
Mark Weinberger, Director

Stock Performance Indicators

Current Sentiment - JNJ

Johnson Johnson Investor Sentiment

Predominant part of Macroaxis users are currently bullish on Johnson Johnson. What is your judgment towards investing in Johnson Johnson? Are you bullish or bearish?
98% Bullish
2% Bearish

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also see Risk vs Return Analysis. Please also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.